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Abstract: Toll-like receptors (TLRs) are a large family of pattern recognition receptors.  
TLR signals are involved in the pathogenesis of systemic lupus erythematosus. Mouse and 
human B cells constitutively express most TLRs. Many B cell subpopulations are highly 
responsive to certain TLR ligation, including B-1 B cells, transitional B cells, marginal 
zone B cells, germinal center B cell and memory B cells. The B cell-intrinsic TLR signals 
play critical roles during lupus process. In this review, roles of B cell-intrinsic TLR2, 4, 7, 
8 and 9 signals are discussed during lupus pathogenesis in both mouse model and patients. 
Moreover, mechanisms underlying TLR ligation-triggered B cell activation and signaling 
pathways are highlighted. 
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1. Introduction 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by 
accumulation of anti-nuclear autoantibodies, hyperactivation of immune cells and multiple organ 
damages triggered by immune complexes deposition [1–4]. Overactivation of innate immune response 
mediated by pattern recognition receptors (PRRs) including toll-like receptors (TLR) is observed in B 
cells and myeloid cells in various mouse models and patients of SLE [5–8]. Although TLR signals are 
not essentially required for B cell activation, B cell-intrinsic TLR signals can drive cell proliferation 
and differentiation, amplify anti-dsDNA autoantibody and cytokine production [9–12]. Certain bacteria 
products and endogenous proteins have been identified to trigger TLR signals. In particular, numerous 
endogenous products derived from necrotic cells including nucleic acids, high-mobility group protein 
B1 (HMGB1), heat shock proteins (HSPs) as well as nucleic acid antigen-autoantibody formed 
immune complexes are involved in B cell overactivation via TLRs and activate T cell-independent 
antibody response in lupus development [13–15]. The endogenous TLR ligands have recently been 
reviewed [16,17]. For instance, endogenous HMGB1 could trigger TLR2, TLR4 and TLR9 activation 
whereas endogenous HSP60 and HSP70 only ligate TLR2 and TLR4. 
The B cell pool consists of B-1 cells and conventional B-2 cells. Abundant amount of B-1 cells are 
located in coelomic cavities, but rarely exist in spleen and peripheral lymph nodes. In the peritoneal 
cavity, B-1 cells are divided into CD5+ B-1a and CD5− B-1b subsets with surface CD11b expression. 
An expanded population of CD11b+ B-1 cells has been described in peripheral blood mononuclear cells 
(PBMCs) of SLE patients [18]. Splenic conventional B-2 cell compartment includes newly formed B cells, 
immature transitional B cells, mature follicular (FO) B cells, mature marginal zone (MZ) B cells, germinal 
center (GC) B cells, memory B cells and plasma cells. The abnormal expansion of transitional stage 2 (T2) 
B cell population is observed in SLE patients [19]. Most available studies on MZ B cells are performed in 
lupus-mouse models. The populations of autoantibody produced GC B cells and IgG+ memory B cells are 
increased in PBMCs and tonsil of SLE patients [20]. The abnormal responses of B cells, especially the 
pathogenic role of B cell-derived autoantibodies, have been extensively discussed [21,22]. In particular, 
TLR activation in B cells can trigger and enhance autoantibody production [23]. 
This review focuses on recent evidence regarding the involvement of B cell-intrinsic TLR signals 
during lupus pathogenesis with an emphasis on the contribution of B cell-specific TLR2, 4, 7, 8 and 9 
to lupus progression. Current understanding and future perspectives of B cell-intrinsic TLR signals and 
their downstream key mediators in lupus pathogenesis are also discussed. 
2. TLR Signal-Sensitive B Cell Subsets in Lupus 
Both B1a and B1b cells from B-1 cells and newly formed B cells, transitional B cells, FO B cells, MZ 
B cells from conventional B-2 cell pool can recognize TLR ligands, but they show differential responses 
to TLR ligation. More sensitive TLR signals are found in B-1 cells and MZ B cells. Increased number of 
B-1 cells is observed in lupus-prone mice and peripheral blood of SLE patients [18,24,25]. Similarly, the 
enlarged population of MZ B cells is also detected in lupus-prone BXSB mice and markedly contributes 
to anti-dsDNA autoantibody production [26,27]. Besides B-1 cells and MZ B cells, transitional B cells, 
germinal center B cells and memory B cells are also highly responsive to certain TLR ligation (Figure 1). 
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Figure 1. TLR signals in B cell subpopulations. B-1 cells, transitional B cells, marginal 
zone B cells, germinal center B cells as well as memory B cells are responsive to TLR 
ligation. B-1 cells are highly sensitive to the ligation of TLR, 2, 4, 7 and 9. CpG ligates the 
TLR9 in transitional B cells. Marginal zone B cells are more sensitive to the ligation of 
LPS and CpG. Germinal center B cells respond to TLR4 ligation whereas TLR9 is highly 
expressed in CD27− memory B cells. 
2.1. B-1 Cells 
B-1 cells, generated from B-1 cell-restricted progenitors with self-renewal property, are characterized 
with a phenotype of CD19hi CD23− CD43+ IgMhi IgD(variable) CD5± [28–30]. Peritoneal cavity B-1 cells and 
B-1 derived plasma cells in bone marrow are considered to be the major source of natural IgM [31,32]. 
The role of B-1 cells in lupus has been extensively investigated [33]. Upon the elimination of B-1 
cells, markedly reduced anti-nuclear autoantibody (ANA) levels with ameliorated lupus nephritis have 
been detected in lupus-prone NZB/W F1 mice, suggesting that peritoneal B-1 cells may play a 
pathogenic role during lupus process [34]. Although hypotonic shock for B-1 cell depletion applied in 
these studies may evoke other cell responses such as serum platelets and epithelia [35,36], the number 
of T cells and conventional B-2 cells are rarely influenced. Nevertheless, how exactly B-1 cells 
contribute to lupus pathogenesis still needs further investigation. 
B-1 cells are known to express TLRs and respond to TLRs ligation. Surface TLR2, 4 and 
intracellular TLR7, 9 are highly expressed in mouse B-1 cells [37]. Certain TLR ligands such as 
CpG1668, LPS, R848 and Pam3CSK4 can selectively promote B-1 cell differentiation [38]. Upon the 
ligation of TLR4 by LPS, B-1 cells from peritoneal cavity produce a large amount of interleukin-10 
(IL10) and inhibit T cell-derived tumor necrosis factor-α (TNFα) secretion [10]. Under the stimulation 
of CpG, both B1a and B1b cells produce an approximate amount of ANA IgM. Interestingly, 
compared with B1a cells, CpG-treated B1b cells exhibit a more profound proliferative response with 
two-fold increase in total cell number. These findings suggest that the major effect of TLR9 signaling 
is the promotion of antibody secretion in B1a cells but enhancement of cell proliferation in B1b cells. 
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Recent studies have shown that a key downstream adaptor of TLR9, paired immunoglobulin  
(Ig)-like receptor B (PIR-B) is activated in B-1 cells upon CpG stimulation. Ligation of TLR9 
promotes the phosphorylation of PIR-B in B-1 cells. In Pirb−/− MRL-Faslpr/lpr mice, accumulated B-1 
cells show overactivation of Btk and NF-κb with severer lupus glomerulonephritis [39], indicating  
a regulatory role of B-1 cell-intrinsic TLR9-PIR-B signaling in lupus mouse model. Furthermore, B1b 
cells are significantly impaired in lupus-prone FcγRIIB−/−TLR9−/− mice, while the number of B1a cell 
remains comparable. Adoptive transfer of wild type (WT) FcγRIIB−/− B1b cells could significantly 
reverse the severe lupus nephritis in FcγRIIB−/−TLR9−/− mice [40]. These results highlight the different 
responses towards TLR ligation in B1a and B1b cells during lupus development. 
2.2. Transitional B Cells 
Transitional B cells are immature B-2 cells existing in peripheral blood and secondary lymphoid organs. 
After migrating into the spleen, transitional B cells differentiate into either follicular B cell (FO B cells) or 
marginal zone B cell (MZ B cells) [41]. TLR9 is highly expressed in human transitional B cells. Rita 
Carsetti’s Group shows that ligation of TLR9 with CpG can drive the differentiation of transitional B cells 
into IgM+ memory B cells and natural IgM-secreting plasma cells [42]. Recent studies by Christophe 
Jamin’s group demonstrate that ligation of TLR9 with CpG could specifically promote human transitional 
B cell differentiation into ANA-producing “CD24− CD38+ CD21high CD23low IgMhigh IgDlow Notch2high” 
MZ B cells, which may play an important role in autoimmune responses [43]. Taken together, these 
findings have revealed the effect of TLR9 signal on promoting transitional B cell differentiation. 
2.3. Marginal Zone B Cells 
Marginal zone B cells are a distinct non-recirculating B-2 cell population, which are located  
in the marginal zone (MZ) region of the spleen [44]. In lupus-prone B6.TC mice that express the 
NZM2410-derived Sle1, Sle2 and Sle3 susceptibility loci, the expanded MZ B cell population is 
observed. MZ B cells from lupus-prone B6.TC mice show a much stronger response to the ligation of 
LPS, CpG and chromatin-immune complexes (ICs) with markedly enhanced cell proliferation and 
production of anti-ssDNA, anti-dsDNA and total IgM [45]. MZ B cells from lupus-prone B6.TC mice 
produce more IL6 than WT mice whereas levels of MZ B cell-derived IL10 remain comparable [46].  
It is known that LPS could promote MZ B cells to secret IL10. However, MZ B cells can secret IL6 
upon the treatment of LPS in combination with CD40L [12], indicating the different underlying 
mechanisms for IL10 and IL6 production by MZ B cells in lupus-prone mice. 
Currently, it is unclear whether MZ B cells play a pathogenic role in lupus process. A MZ B cell-derived 
population with two types of light chains (or more rarely H chains) has been observed in mouse model, 
which is characterized by autoantibody production and higher sensitivity to TLR7-induced  
proliferation [47]. In double H chain transgenic mice (3H9H/56R.B6 and MRL/lpr-Igkm/h), the 
amplified κ/λ double-positive B cells are identified within the MZ B cell population, which shows the 
origin of double-positive B cells [48–50]. Furthermore, naive B cells from SLE patients show a 
polyreactive autoantibody response with significantly impaired immunoglobulin κ chain region 
variation, indicating that the generation of κ/λ double-positive B cells may be due to aberrant 
processing of early B cell tolerance in lupus [51]. 
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MZ B cells are more responsive to TLR ligation than FO B cells. LPS has been shown to promote the 
differentiation of MZ B cells but rarely trigger cell differentiation in FO B cells [52]. One of the mechanisms 
in TLR-mediated B cell activation is that TLR ligation with LPS or CpG could modulate B-cell sensitivity to 
membrane bounding antigens by formation of F-actin-rich membrane ruffles, a process that is mediated by 
the activation of cofilin. MZ B cells are much more sensitive to cofilin activation than FO B cells [53]. 
Besides the in vitro sensitivity to TLR ligation in MZ B cells, a marginal zone-restricted CD169+ 
metallophillic macrophage population can capture apoptotic cells and produce CCL22 to induce a regulatory 
response in vivo. By using CCR4 antagonist to block CCL22 for disrupting the location of CD169+ 
metallophillic macrophage, a higher anti-dsDNA IgG level is observed, which indicates that the function of 
MZ B cells may be modulated by their interaction with tissue-resident macrophages as well [54]. 
2.4. Germinal Center B Cells 
It has been reported that the spontaneous germinal center (GC) response is evident in lupus-prone 
BXD2 mice whereas increased frequency of autoreactive GC B cells exists in lupus patients [20,55,56]. 
Recent studies have revealed that the differentiation of GC B cells is induced by CD40L, IL21 and IL4 
provided from follicular T cells [57,58]. In addition, GC B cells also respond to TLR ligands, 
especially TLR4 ligands. In spite of the comparable level of TLR4/MD2 surface expression among GC 
B cells, FO B cells and MZ B cells, GC B cells have as a strong response to LPS-induced proliferation 
as MZ B cells. Moreover, LPS-stimulated IgM and IgG production is diminished in MyD88−/− B cells, 
suggesting that the effect of LPS is dependent on MyD88 in GC B cells [52]. In summary,  
TLR4-MyD88 signal is critically involved in autoreactive GC B cell response. 
2.5. Memory B Cells 
In the peripheral blood of SLE patients, an increased number of CD27− IgD− memory B cells is 
observed, which is thought to be one major source of ANAs. Memory B cells constitutively express  
TLR9 [59]. CD27− IgD− memory B cells are highly responsive to CpG-induced cell proliferation. Recently, 
a novel population of ANA-secreting CD27− Syk++ memory B cells has been identified in the peripheral 
blood of SLE patients, among which 30% are IgD− memory B cells, indicating that they are either two 
identical populations or overlapped atypical memory B cells. The ligation of TLR4 by LPS has been  
shown to promote the expansion of CD27− Syk++ memory B cells, although underling mechanisms are  
still unknown [60,61]. Currently, the origin of CD27− memory B cells remains largely unclear. However, 
CD27low B cells have been found in the marginal zone region of human spleen. Future studies may provide 
more insight into understanding the role of memory B cells during the development of SLE. 
3. B Cell-Intrinsic TLR Signals in Lupus 
Most TLRs are constitutively expressed in mouse and human B cells [62]. The elevated levels of 
TLR3, TLR7 and TLR9 in CD19+ B cells from PBMCs of SLE patients are detected. In particular, the 
increased level of TLR9 in B cells is highly correlated with organ damage in lupus patients [63,64]. 
TLR7 and TLR8 are encoded by X-linked genes, which may render females more susceptible to  
lupus [65,66]. Differential responses to TLR ligation are observed between humans and mice. Murine 
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B cells are highly sensitive to LPS stimulation via TLR4, while human peripheral blood B cells are not 
responsive to LPS though tonsil B cells show TLR4 expression [67]. Murine B cells are strongly 
responsive to TLR2 ligation, but human B cells need BCR activation to trigger TLR2 signal [62].  
The extracellular domains of mammalian TLRs from many species have been analyzed by drawing a 
neighbour-joining molecular tree, which shows that the sequences of human extracellular domains of 
mammalian TLRs are similar with rat than mice by branch lengths, suggesting the variability of 
structural and ligation properties between human and mice TLRs [68]. 
It has been reported that TLR7, TLR8 and TLR9 polymorphisms are associated with the disease 
incidence of SLE [69–71]. Based on recent studies of B cell function in mice lupus models, roles of  
B cells-intrinsic TLR, 2, 4, 7, 8, 9 signals during lupus pathogenesis are herein discussed (Table 1). 
Table 1. TLRs in B cells and lupus pathogenesis. 
Toll-Like 
Receptor 
Express Pattern  
on B Cells 
Roles of TLR in  
B Cells 
Relevance with  
SLE Patients 
Lupus Pathogenesis in  
Mouse Model 
TLR2 Surface expression on 
B-1 and MZ B cells. 
MZ B cell expansion;  
B-1 cells differentiation. 
Unknown. LTA (TLR2 ligand)-injection in MRL-Faslpr/lprmice ↑; 
Pristane-induction in TLR2−/− mice ↓;  
TLR2−/− B6-Faslpr/lpr mice ↓;  
TLR2−/− MRL-Faslpr/lpr (N/A). 
TLR4 Surface expression on 
B-1, MZ B, GC B and 
CD27− Memory B cells. 
MZ B proliferation and 
differentiation;  
IL10 production;  
B-1 differentiation;  
GC B proliferation;  
CD27− memory  
B cells proliferation. 
Accumulated RP105− 
B cells observed. 
LPS (TLR4 ligand)-injection in MRL-Faslpr/lpr mice ↑; 
LPS (TLR4 ligand)-injection in NZB/W F1 mice ↑;  
Pristane-induction in TLR4−/− mice ↓. 
TLR7 Surface and intracellular 
expression on B-1 and 
MZ B cells. 
T1 B cells and  
FO B cells expansion;  
IL6 production;  
B-1 cells differentiation. 
Increased in B cells; 
Gene polymorphisms 
associated  
with disease. 
imiquimod (TLR7 agonist) injection in WT mice ↑;  
R848 (TLR7 agonist) injection in WT mice ↑;  
Transgenic Sle1Tg7 mice ↑;  
Reconstituted was−/−tlr7−/− B cell-μMT mice ↓;  
Reconstituted 3H9 TLR7−/Yaa.NZW/ BXSB BM-WT 
mice ↓. 
TLR8 Surface and intracellular 
expression on B cells. 
Controlling TLR7 activation. Increased in B cells; 
Gene polymorphisms 
associated  
with disease. 
TLR8−/− Nba2.Yaa mice ↑;  
TLR8−/− mice ↑;  
TLR8−/− TLR9−/− mice ↑;  
TLR8−/− TLR7−/− mice ↓. 
TLR9 Surface and intracellular 
expression on B-1,  
MZ B, Transitional B 
and CD27− Memory  
B cells. 
B1a antibody secretion;  
B1b proliferation;  
T2 B cell differentiation;  
MZ B cell proliferation and 
differentiation;  
CD27− memory B  
cells proliferation. 
Increased in B ccells; 
Gene polymorphisms 
assosiated  
with disease. 
Oligodeoxynucleotides (TLR9 ligand) injection in 
NZB/W F1 mice ↓;  
Reconstituted was−/−tlr9−/− B cell-μMT mice ↑;  
TLR9−/− MRL-Faslpr/lpr mice ↑ and TLR9−/− Jh−/−  
MRL-Faslpr/lpr mice (N/A);  
TLR9−/− CD45E613R BALB/c mice ↓. 
↑ accelerated lupus pathogenesis; ↓ ameliorated lupus pathogenesis; (N/A) no difference; MZ marginal zone; 
GC germinal center. 
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3.1. TLR2 
Administration of TLR2 ligand lipoteichoic acid (LTA) into MRL-Faslpr/lpr mice has been found  
to promote spontaneous lupus pathogenesis with distinct neuronal dysfunction. Increased IgM− IgG+ 
B220+ cells and expansion of CD21+ CD23+ B cells have been observed in LTA injected MRL-Faslpr/lpr 
mice [72]. In pristane-induced lupus mouse model, TLR2−/− mice show lower ANA levels and reduced 
lupus pathogenesis, together with a reduced level of HMGB1, a well-known endogenous TLR  
ligand [73]. Moreover, reduced ANA levels, ameliorated glomerulonephritis and decreased expansion 
of MZ B cells population are also observed in TLR2−/− B6-Faslpr/lpr mice. However, further studies on 
MRL-Faslpr/lpr mice reveal that TLR2 deficiency has no impact on lupus pathogenesis [74]. Based on  
the pristane-induced lupus model is also performed in B6 background, one possibility for these 
contradicting findings in TLR2−/− mice is that TLR2 gene polymorphism between B6 and MRL mice 
strains may contribute to the different outcomes to TLR2 deficiency in lupus development. 
3.2. TLR4 
Several studies have shown that LPS, a TLR4 ligand, can promote lupus nephritis and autoantibody 
production in lupus-prone MRL-Faslpr/lpr mice and NZB/W F1 mice [9,75]. Ameliorated autoantibody 
production and glomerulonephritis are found in TLR4−/− pristane-induced lupus model and lupus-prone 
TLR4−/− B6. Faslpr/lpr mice [73,74]. 
Besides the bacterial product LPS, many endogenous products could also bind to TLR4.  
The activation of TLR4 signal needs the surface signalosome formation by binding with MD-2 and 
CD14, while RP105/MD-1 complex can negatively regulate the activation of TLR4/MD2 [76]. It has 
been shown that surface RP105 directly blocks the TLR4 ligation in cell lines [77,78]. Further analysis 
of both TLR4/MD2 and RP105/MD-1 reveals a high level of RP105/MD-1 expression in MZ B cells. 
MZ B cells respond to the ligation of TLR4, RP105 or both, resulting in cell differentiation and  
antibody production. Activation of RP105/MD-1 has been found to promote TLR4-induced MZ B cell 
proliferation and survival. However, RP105/MD-1 alone could not drive MZ B cell differentiation [79]. 
The physical binding with MD-1 is necessary for the function of RP105. Interestingly, increased serum 
sMD-1 level is observed along with lupus progression in MRL-Faslpr/lpr mice [80]. In RP105−/− mice, B 
cell proliferation in response to LPS stimulation is not affected, suggesting a B cell-independent 
regulation of TLR4 signal by RP105 [81]. 
BCR, IL6r or CD40 activation through regulating intracellular p-ERK localization could reverse  
LPS-induced autoantibody production by B cells from 2-12H.B6 mice [82]. In lupus-prone 2-12H.  
MRL-Faslpr/lpr mice, the regulatory role of IL6 and CD40 in LPS-induced B cell differentiation is not 
evident, which might be related with elevated basal p-ERK level in lupus-prone B cells [82]. Besides 
its interaction with BCR and CD40, TLR4 signal in B cells also has crosstalk with TNFα. DCs and 
macrophages-derived TNFα could inhibit the LPS-induced B-cell autoantibody production. Notably, 
LPS could induce severe ANAs production in TNFα−/− mice [83], indicating a complicated crosstalk of 
TLR4 with BCR, CD40 and TNFα signals in autoreactive B cells. 
Moreover, LPS has been considered as an important immune adjuvant, while stimulation of TLR4 
could inhibit the antigen-specific immune response through a regulatory role in myeloid cells [84].  
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As a matter of fact, LPS or apoptotic cells alone could promote IL10 secretion in MZ B cells [12,46], 
while in MRL-Faslpr/lpr mice, specific depletion of IL10 in CD19+ B cells does not exacerbate lupus 
nephritis. Evidence suggesting that B cell-derived IL10 may play an insignificant role during lupus 
progression in lupus-prone MRL-Faslpr/lpr mice [85]. 
Despite the lower surface TLR4 level in human B cells, RP105 is highly expressed in naive human 
B cells. The population of ANAs-secreting RP105− B cell is expended in lupus patients, with the 
activated B cell phenotype “IgD− CD38+ CD95+ CD86+” [86,87]. Furthermore, accumulated RP105− B 
lymphocytes with ANAs and IL6 production are also observed in lupus-prone NZB/W F1 mice [88]. 
3.3. TLR7 
Many studies in lupus models have indicated a pathogenic role of TLR7 during lupus development. 
Administration of TLR7 agonists (imiquimod and R848) can induce lupus nephritis with increased 
serum ANA levels, especially anti-dsDNA IgG levels, in which enhanced activation of autoreactive B 
cells might be responsible for the autoantibody production [89]. Moreover, blockage of TLR7 or 
TLR7/9 pathway with immunoregulatory sequences attenuates lupus pathogenesis in MRL-Faslpr/lpr 
mice [90]. 
Recent studies have examined the role of B cell-intrinsic TLR7 by using mouse models with B  
cell-specific overexpression or deletion of TLR7. In a low-copy TLR7 transgenic B6-Sle1 mouse 
model (Sle1Tg7), severe autoimmune response and accelerated nephritis have been observed. Further 
normalization of TLR7 expression in B cells is found to rescue the severe lupus phenotypes in Sle1Tg7 
mice [91]. 
Studies using B cell specific deficiency of Wiskott-Aldrich syndrome protein (WAS) as a lupus  
mice model also shows significantly elevated ANA levels and glomerulonephritis. By reconstitution of 
was−/− or was−/−tlr7−/−B cells in μMT mice, ameliorated lupus pathogenesis has been observed in 
was−/−tlr7−/−B cells chimeric mice [92,93]. A recent report using anti-CL/DNA autoantibody 3H9.GFP 
transgenic mice in lupus-prone NZW/BXSB background has determined the role of TLR7 signal in the 
differentiation of autoreactive (3H9) B cells. Lower frequencies of GC B cells and plasma cells, 
together with ameliorated lupus clinical score are observed in the chimeric mice reconstituted with the 
bone marrow of 3H9 TLR7−/Yaa NZW/BXSB mice in comparison with the bone marrow from 3H9 WT 
mice, indicating that TLR7 is essential for the spontaneous germinal center response including B cell 
expansion and diversification in lupus-prone mice [94]. 
Recent studies have supported the notion that TLR7 is crucial for B cell proliferation and  
survival [92,93]. The overexpression of TLR7 in TLR7.1Tg mice results in significantly expanded 
transitional stage 1 B (T1 B) and FO B subpopulations but decreased number of MZ B cells. In WT 
(Ly5.1+) and TLR7.1Tg (Ly5.2+) bone marrow reconstituted mice, increased T1 B cell proliferation is 
specifically observed in TLR7.1Tg B cells, together with increased apoptosis in both T1 and MZ B  
cells. These data may suggest that an enhanced response of TLR7.1Tg T1 B cells to TLR7 ligation 
induces cell proliferation and ANA production. Interestingly, the reduced MZ B cell population in 
TLR7.1Tg mice is dependent on type I IFN signaling [95]. It is clear that TLR7 could be expressed on 
surface and in intracellular location of B cells, especially in MZ B cells. Upon the internalization of  
anti-TLR7 antibody binding with surface TLR7, the ligation of TLR7-induced B cells proliferation is 
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largely blocked [96]. However, activating TLR7 by CL095 together with co-activation of BCR can 
promote IL6 production by B cells, especially in B cells from lupus-prone mice [97]. 
In human naïve B cells and memory B cells, the ligation of TLR7 by R848 and CpG2006 can  
promote cell proliferation and IL6 secretion. Additionally, IFNα could amplify the induced IgG and 
IgM production by R848 in naïve and memory B cells. However, the ligation of TLR2 and TLR4 only  
shows mild effects on B cell proliferation [98]. Recent reports have demonstrated that B cells from 
SLE patients have higher activation and necroptosis. Ligation of TLR7 and BCR directly triggers 
necroptotic B cells formation, which may contribute to B cell lymphopenia in SLE patients [99]. 
3.4. TLR8 
TLR8 is one of the X-linked TLRs. The high level of TLR8 in B cells from lupus-prone 564Igi mice 
is directly related to ANAs production and contributed to the lupus-like pathogenesis in female 564Igi 
mice [65]. Estrogen treatment has been found to increases the expression level of TLR8 [100]. 
Notably, overexpression of TLR8 is correlated with local injury in glomerulonephritis [101]. 
Intriguing findings have been obtained from TLR8 deficient lupus-prone Nba2.Yaa mice, in which 
accelerated lupus nephritis and splenomegaly is observed, together with enhanced response to TLR7 
ligation [102]. Both TLR8−/− and TLR8−/− TLR9−/− mice could develop lupus phenotype by lacking 
their inhibitory effects on TLR7 signal. In comparison to WT mice, MZ B cells, B1a and B1b cells are 
impaired in both TLR8−/− and TLR8−/− TLR9−/− mice. The response of TLR8−/− B cells to R848 ligation 
remains normal, but increased IL6 secretion and CD86 expression in TLR8−/− BM-derived DCs are 
observed [103]. Ligation of R848 in TLR8−/− TLR9−/− B cells results in the production of large amount 
of autoantibodies. These findings indicate that cell-specific TLR8 and TLR9 signals are important in 
regulating lupus development. In conclusion, TLR8 mediates DC-dependent autoantibody production, 
while TLR9 mediates B cell-intrinsic autoantibody production. Moreover, TLR8−/− TLR7−/− mice show 
ameliorated lupus pathogenesis as well as restored MZ B cell population [104], indicating a critical 
function of TLR8 in controlling TLR7 activation [65]. 
3.5. TLR9 
Several studies have investigated the role of TLR9 signal in lupus-prone mice. Administration of 
oligodeoxynucleotides (ODN) with TTAGGG motifs is found to trigger TLR9 activation and block  
anti-dsDNA autoantibody production in NZB/W F1 mice [105]. Accelerated lupus pathogenesis in 
TLR9−/− C57 background mice was reported, in which mild ANA production with overactivated TLR7 
signal in TLR9−/− B cells is observed [103]. 
With reconstitution of was−/− or was−/−tlr9−/− B cells in μMT mice, severe lupus pathogenesis has 
been found in was−/−tlr9−/− B cells chimeric mice [92,93]. Other studies have examined the chimeric 
mice with the bone marrow of TLR9−/− MRL-Faslpr/lpr mice and TLR9−/− Jh−/− MRL-Faslpr/lpr mice to 
evaluate the B cell-intrinsic TLR9 signal in lupus process. The population of anti-DNA B cells in the 
spleen and lymph node is expanded in TLR9−/− MRL-Faslpr/lpr mice, while the uptake of BrdU is even 
lower in expanded anti-DNA B cells, suggesting that TLR9 signal restricts the survival of anti-DNA  
B cells [106]. These findings suggest that B cell-intrinsic TLR9 plays a regulatory role during lupus 
Int. J. Mol. Sci. 2015, 16 13093 
 
 
pathogenesis. However, contradictory findings have been obtained from mice in TLR9−/− BALB/c 
mice, which do not show ANA production. 
Furthermore, a point mutation (CD45E613R) in the autoreactivity-associated locus on chromosome 
9 causing constitutively CD45 activation could induce a BALB/c background-dependent ANA 
production, which is related to TLR9 signal overactivation. By transferring an equal amount of IgHb 
WT and IgHa CD45E613R bone marrow into WT hosts, all of ANA-secreting cells are generated from 
CD45E613R mice. Strikingly, in combination with TLR9 deficiency, the ANA production is 
diminished in CD45E613R mice, indicating a TLR9-dependent autoreactive B cell-intrinsic manner in 
production of ANAs. The difference of TLR9 signal between BALB/c and C57 genetic backgrounds is 
probably due to five non-synonymous coding changes located in intracellular toll/IL-1R domain [107]. 
TLR9−/− B cells highly respond to the stimulation of RNA-associated ICs in vitro and in vivo, with 
increased cell proliferation, survival and IgG-secreting cells. 
Although comparable TLR7 levels are observed in WT and TLR9−/− B cells, double knock of TLR7 
and TLR9 could block the overactivation of TLR9−/− B cells [108]. TLR9-stimulated autoreactive  
B cell activation is dependent on the binding of the receptor for advanced glycation end products  
(RAGE) [109]. RAGE deficiency enhances lymphoproliferation with ANA production and lupus 
nephritis presented in B6-MRL-Faslpr/lpr mice [110]. This finding could partially explain the regulatory 
role of TLR9 in lupus process. Moreover, generation of rheumatoid factor (RF) autoreactive B cells is 
dependent on the ligation of TLR9 [15]. Located at the extra-follicular clusters of both lupus-prone 
MRL-Faslpr/lpr mice and B6.Sle1.Sle2.Sle3 (TC) mice, RF B cells can differentiate into RF plasmablasts 
with the immunization of anti-chromatin IgG2aa ICs through TLR9 dependent pathway [111,112]. 
TLR9 is expressed in both surface and intracellular region of human B cells. CpG could specifically 
bind to endosomal TLR9 while anti-TLR9 antibody binds to surface TLR9. Although ligation of 
endosomal TLR9 with CpG could promote B cells proliferation, the ligation of surface TLR9 with  
anti-TLR9 antibody blocks both CpG and anti-BCR induced cell proliferation in human B cells [113]. 
Thus, the molecular mechanisms underlying opposite functions of endosomal and surface TLR9 need  
to be further investigated. 
Available clinical findings show increased percentage of TLR9+ B cells in PBMCs from active SLE 
patients, and the treatment of active SLE serum could increase TLR9 level in B cells [64]. Recent studies 
observed the reduced protein level and signaling response of TLR9 in B cells from severe SLE patients. 
Impaired cell proliferation and reduced cytokines (IL6, IL9, IL17A, IFN-γ, MIP-1α and TNF-α) 
production are observed in CpG triggered B cells from severe SLE patients, suggesting an exhausted 
status of TLR9 signal in SLE patients [114]. 
4. Key Mediators in B Cell-Intrinsic TLR Signal 
Toll/IL-1R (TIR)-domain-containing adaptors including Myeloid Differentiation Primary Response 
Gene 88 (MyD88), toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) and  
TIR-domain-containing adapter-inducing interferon-β (TRIF), which are essential for transducing the TLR 
signals. Recent studies have shown that many TLRs share the same downstream adaptor MyD88 except 
TLR3 [62]. TLR2- and TLR4-mediated signaling pathways are dependent on TIRAP activation [115,116] 
whereas analog poly(I:C) triggered TLR3 ligation leads to upregulation of TRIF [117]. 
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Internalization of intracellular TLRs including TLR7, TLR8 and TLR9 is dependent on a chaperone 
protein Unc-93 Homolog B1 (C. elegans) (Unc93b1) [118]. Upon the ligation of TLRs, MyD88 is 
recruited whereas Unc93b1 is circulated within B cells. Herein, the mechanisms of MyD88 and 
Unc93b1 in TLR-triggered signaling pathways in B cells are discussed. 
4.1. MyD88 
B cell-intrinsic MyD88 is essential for plasmablast generation, ANA autoantibody secretion in  
MRL-Faslpr/lpr mice. CD19-cre mediated MyD88 depletion in B cells ameliorates lupus nephritis in 
MRL-Faslpr/lpr mice [119]. MyD88 is responsible for LPS-induced B cell proliferation, cell division and 
CD86 up-regulation. In contrast, TRIF is indispensable for IL4 and LPS stimulation-induced Aicda 
expression and μ to γ1 or ε class switch recombination [120]. Based on the protein structure of death 
domain, MyD88 could bind to several molecules for signal transduction including IFN regulatory 
factors (IRF4, IRF5 and IRF7) [121–124]. IRF-5 and IRF-7 mediate the secretion of proinflammatory 
cytokines and type I interferons (IFNs) by interacting with MyD88. However, IRF4 negatively 
regulates TLR ligation induced IL6, IL12p40 production by binding to MyD88. IRF4−/− mice  
are hypersensitive to TLR stimulation [121]. In IRF4 deficiency C57BL/6-lpr/lpr mice, enhanced  
cytokine production is observed, while lack of plasma cell and reduced autoantibody level leads to 
ameliorated lupus nephritis [125]. Besides IFN regulatory factors, MyD88 could also bind to single 
immunoglobulin IL-1R-related protein (SIGIRR). SIGIRR is an inhibitory membrane receptor, which 
could block TLR4 and TLR9 activation by competitively binding to downstream adaptors as revealed by 
the findings that SIGIRR−/− splenocytes are highly-responsive to LPS and CpG ligation [126]. Lack of 
SIGIRR accelerates lupus nephritis in C57BL/6-lpr/lpr mice and hydrocarbon oil-injected mice [127,128]. 
Lyn deficiency has been shown to induce lupus nephritis, and B cell-specific Lyn deficiency also 
leads to the development of lupus nephritis [129]. Interestingly, the disease progression of CD19  
cre-Lyn−/− mice is similar to Lyn−/− mice. Increased plasma cells, B-1 cells and myeloid cells, together 
with increased serum IL6 and BAFF levels are observed in CD19 cre-Lyn−/− mice. When combining 
with the depletion of MyD88 in CD19 cre-Lyn deficient mice, the phenotypes of plasma cell 
differentiation and lupus nephritis are reversed, suggesting that Lyn play an inhibitory role in  
MyD88-mediated autoreactive B cell generation in lupus-prone mice [130]. 
4.2. Unc93b1 
The internalization and trafficking of nucleic acid-sensing TLRs (including TLR3, 5, 7, 8, 9) are 
dependent on a chaperone protein Unc93b1 [118,131]. In lupus-prone MRL-Faslpr/lpr and BXSB 
background [132], Unc93b1 deficiency can dampen ANA levels and ameliorate lupus nephritis.  
In WT (IgHa):3d (Unc93b1−/−) (IgHb) reconstituted chimeric mice, ANA secreting cells are generated 
from WT B cells, demonstrating that Unc93b1 is indispensable for B cell-intrinsic autoantibody 
production [133]. 
The D34 site in Unc93b1 is important for its binding to TLRs. TLR9 and TLR7 competitively  
bind to Unc93B1 at D34 site. Without D34, TLR7 is dominantly binding to Unc93b1 and triggering 
inflammatory response. In Unc93b1D34A/D34A mice, TLR7-dependent inflammation and B cell-intrinsic 
TLR7 overactivation are evident. Imiquimod activated TLR7 signal is enhanced in Unc93b1D34A/D34A  
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B cells, while impaired CpG triggered TLR9 signal and comparable lipidA activated TLR4 signal are 
detected in Unc93b1D34A/D34A B cells [134]. Moreover, levels of surface and interlizated TLR7 are 
much higher in Unc93b1D34A/D34A MZ B cells. By blockage of TLR7, systemic immune response is 
blocked in Unc93b1D34A/D34A mice [96]. Further mechanistic studies reveal that Unc93b1 plays 
different roles in the trafficking of TLR7 and TLR9. Unc93b1 is required in both ER exit and  
post-Golgi trafficking of TLR9 by binding to AP-2. However, the ER exit process of the intracellular 
TLR7 trafficking is dependent on Unc93b1 whereas Unc93b1/AP2 complex is not required during this 
process [135]. 
5. Conclusions and Future Perspectives 
B cell-intrinsic TLR signals are crucial for the generation and expansion of autoreactive B cells.  
This unique signaling process is involved in the pathogenesis of lupus [5]. Since TLRs are also 
considered as promising therapeutic targets in SLE [136], several biological products have been  
designed for targeting TLRs, including blocker of TLR7 (IRS661), antagonist of TLR7/8/9 
(Chloroquine), inhibitor of TLR2/4 (Vitamin D3). Moreover, antagonist of TLR7/9 (IRS954) and 
antagonist of TLR7/8/9 (CPG52364) are in clinical phase I stage. In addition, antagonist of TLR7/8/9 
(IMO8400) and antagonist of TLR7/9 (IMO3100) are currently in preclinical stage [137]. 
However, many issues need to be addressed before the clinical application of targeting TLRs.  
The different effects between human and mouse TLR signals suggest that current mouse models might 
not be the most appropriate platform for determining the role of TLRs in vivo. Thus, it becomes 
important to constitute the entire human immune system in humanized mice for further investigating 
the TLR signal. It is equally important to determine whether the blockade of TLR signals may increase 
the susceptibility to infection. In particular, infection in SLE patients promotes the disease progression 
by triggering TLR signals [138]. Thus, it might be more important to modulate the hyperactivated TLR 
signals to the normal level than simply inhibit TLR signals in lupus patients. 
Research findings that antibiotics treatment can ameliorate the systemic immune response in  
TLR4 dependent-lupus prone gp69Tg mice may suggest a pathogenic role of microbiota during  
lupus development. Thus, the usage of antibiotics might be a promising strategy for combined 
therapies for SLE. Since there is compelling evidence that a parasitic worm product ES-62 can induce 
the CD19+ CD21+ CD23+ IL10+ regulatory B cell population in MRL-Faslpr/lpr mice and reverse the 
lupus pathogenesis [139], further studies are needed to validate the therapeutic potential of regulatory 
TLR ligands for the treatment of SLE. 
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